Evidence-Based Complementary and Alternative Medicine / 2015 / Article / Tab 3

Research Article

Effects of Traditional Chinese Medicine on Chemotherapy-Induced Myelosuppression and Febrile Neutropenia in Breast Cancer Patients

Table 3

Multivariate analysis of clinicopathological variables of leukopenia.

VariablesBefore propensity matchingAfter propensity matching
OR 95% CI OR 95% CI

Age0.9890.971–1.0060.199 0.9790.965–0.9940.005
Chemotherapy regimens
 11 1
 20.9760.539–1.7650.935 0.7730.468–1.2740.312
 34.4772.764–7.251<0.0001 3.2082.228–4.617<0.0001
 41.5520.942–2.5580.085 1.2510.837–1.8690.275
TNM stage
 I1 1
 II1.2270.858–1.7560.262 1.3601.014–1.8230.040
 III and IV2.4361.362–4.3570.003 1.9531.215–3.1410.006
Neoadjuvant chemotherapy0.7880.476–1.3040.354 0.5840.377–0.9050.016
ER1.1650.655–2.0710.603 1.2150.772–1.9130.399
PR0.7810.457–1.3330.364 1.0030.654–1.5370.989
HER-20.8570.561–1.3070.473 1.0940.762–1.5720.626
Ki671.1320.791–1.6200.499 1.5521.163–2.0710.003
TCM treatment0.2520.172–0.367<0.0001 0.2850.218–0.373<0.0001

Chemotherapy: 1: the chemotherapy regimens contain AC/EC (Adriamycin or epirubicin, Cyclophosphamide) and CAF/CEF (Adriamycin or epirubicin, Cyclophosphamide, and 5-Fluorouracil). 2: the chemotherapy regimens contain TC (paclitaxel or docetaxel, Cyclophosphamide) and T (paclitaxel or docetaxel). 3: the chemotherapy regimens contain anthracyclines combined with paclitaxel or docetaxel: TAC/TEC (paclitaxel or docetaxel, Cyclophosphamide, and Adriamycin or epirubicin); TA/TE (paclitaxel or docetaxel, Adriamycin or epirubicin). 4: the chemotherapy regimens contain anthracyclines followed by paclitaxel or docetaxel: AC/EC (Adriamycin or epirubicin, Cyclophosphamide); CAF/CEF (Adriamycin or epirubicin, Cyclophosphamide, and 5-Fluorouracil), followed with T or TH (paclitaxel or docetaxel, Herceptin).

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.